N-<2-hydroxy-2-(4-methoxyphenyl)ethyl>-2-(2-bromo-3,4-dimethoxyphenyl)ethylamine | 104113-97-5

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 石蒜科生物碱
• 英文名称: N-<2-hydroxy-2-(4-methoxyphenyl)ethyl>-2-(2-bromo-3,4-dimethoxyphenyl)ethylamine
• 英文别名: 2-[2-(2-bromo-3,4-dimethoxyphenyl)ethylamino]-1-(4-methoxyphenyl)ethanol
• CAS: 104113-97-5
• 化学式: C₁₉H₂₄BrNO₄
• 分子量: 410.308
• InChiKey: VUZDFLFIHQZIRR-UHFFFAOYSA-N

物化性质

• 熔点：
  116.5-118 °C
• 沸点：
  540.6±50.0 °C(Predicted)
• 密度：
  1.318±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.34
• 重原子数：
  25.0
• 可旋转键数：
  9.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  59.95
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  N-<2-hydroxy-2-(4-methoxyphenyl)ethyl>-2-(2-bromo-3,4-dimethoxyphenyl)ethylamine 在 硫酸 、 potassium carbonate 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 三氟乙酸 为溶剂， 反应 0.33h， 生成 3-Allyl-6-bromo-7,8-dimethoxy-1-(4-methoxy-phenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
  参考文献：
  名称：

  Dopamine agonists related to 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol, 6-position modifications

  摘要：

  The N-allyl derivative (SK&F 85174) of 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol (SK&F 82526) retains the DA-1 agonist potency of the latter compound but unlike the parent also shows substantial DA-2 agonist activity. In a previous study of N-substituted benzazepines these combined agonist effects were shown to be uniquely associated with the N-allyl group. A continuation of this research has examined dependency of combined DA-2/DA-1 agonist activities on 6-position modification with the specific objective of developing an agonist with maximum effectiveness and potency at the DA-2 receptor subtype. DA-2 agonist activity was measured in a rabbit ear artery assay, and DA-1 agonist activity was determined in an adenylate cyclase assay. Replacing chloro with bromo retains the activity pattern and the potency of the chloro compound; replacement with a hydrogen causes a decrease of both DA-1 and DA-2 receptor activating potency. Introduction of a 6-methyl group causes loss of DA-2 agonist activity and reduction in DA-1 agonist potency. Substitution with a 6-fluoro provides the best balance of DA-2 and DA-1 agonist activities; this compound was moderately potent in both assays.

  DOI：

  10.1021/jm00384a006
• 作为产物：
  描述：

  2-氨基-1-(4-甲氧基苯基)乙醇 在 硼烷 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 3.0h， 生成 N-<2-hydroxy-2-(4-methoxyphenyl)ethyl>-2-(2-bromo-3,4-dimethoxyphenyl)ethylamine
  参考文献：
  名称：

  Dopamine agonists related to 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol, 6-position modifications

  摘要：

  The N-allyl derivative (SK&F 85174) of 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol (SK&F 82526) retains the DA-1 agonist potency of the latter compound but unlike the parent also shows substantial DA-2 agonist activity. In a previous study of N-substituted benzazepines these combined agonist effects were shown to be uniquely associated with the N-allyl group. A continuation of this research has examined dependency of combined DA-2/DA-1 agonist activities on 6-position modification with the specific objective of developing an agonist with maximum effectiveness and potency at the DA-2 receptor subtype. DA-2 agonist activity was measured in a rabbit ear artery assay, and DA-1 agonist activity was determined in an adenylate cyclase assay. Replacing chloro with bromo retains the activity pattern and the potency of the chloro compound; replacement with a hydrogen causes a decrease of both DA-1 and DA-2 receptor activating potency. Introduction of a 6-methyl group causes loss of DA-2 agonist activity and reduction in DA-1 agonist potency. Substitution with a 6-fluoro provides the best balance of DA-2 and DA-1 agonist activities; this compound was moderately potent in both assays.

  DOI：

  10.1021/jm00384a006

文献信息

• Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogs of fenoldopam
  作者：Joseph Weinstock、David L. Ladd、James W. Wilson、Charles K. Brush、Nelson C. F. Yim、Gregory Gallagher、Mary E. McCarthy、Joanne Silvestri、Henry M. Sarau

  DOI：10.1021/jm00161a029

  日期：1986.11

  Certain 6-halo-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines were found to be potent D-1 dopamine agonists. The 1-(4-hydroxyphenyl) analogues did not have central nervous system activity because their high polarity inhibited entry into the brain. However, these compounds were potent renal vasodilators. Fenoldopam, the 6-chloro analogue, is an especially significant member of the series, and its synthesis

  发现某些6-卤代-1-苯基-2,3,4,5-四氢-1H-3-苯并ze庚因是有效的D-1多巴胺激动剂。1-（4-羟苯基）类似物不具有中枢神经系统活性，因为它们的高极性抑制了其进入大脑。但是，这些化合物是有效的肾血管扩张药。非氯多巴，6-氯类似物，是该系列中特别重要的成员，其合成，药理和临床特性已得到广泛研究。6-甲基和6-碘同系物是有效的肾血管扩张剂，但通过刺激大鼠尾状腺苷酸环化酶测定，非有效的部分D-1激动剂。可能的合理化建议这些活动具有不同的受体储备。9位取代的苯并庚因多巴胺激动剂不活跃或效力低下，
• WEINSTOCK J.; LADD D. L.; WILSON J. W.; BRUSH CH. K.; YIM N. C. F.; GALLA+, J. MED. CHEM., 29,(1986) N 11, 2315-2325
  作者：WEINSTOCK J.、 LADD D. L.、 WILSON J. W.、 BRUSH CH. K.、 YIM N. C. F.、 GALLA+

  DOI：——

  日期：——
• ROSS S. T.; FRANZ R. G.; GALLAGHER G.; BRENNER M.; WILSON J. W.; DEMARINI+, J. MED. CHEM., 30,(1987) N 1, 35-40
  作者：ROSS S. T.、 FRANZ R. G.、 GALLAGHER G.、 BRENNER M.、 WILSON J. W.、 DEMARINI+

  DOI：——

  日期：——